Network analysis methods have shown that statins, which are drugs against dyslipidemia, and lovastatin in particular, are beneficial for patients with gastric cancer due to the inhibition of histone deacetylase 2 (HDAC2), overexpression of which characterizes gastric tumors’ cells [118]. Here, HDAC2 is linked to metabolic syndrome.